The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...
The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...